The new WHO classification for essential thrombocythemia calls for revision of available evidences

Tiziano Barbui, Jürgen Thiele, Alberto Ferrari, Alessandro M. Vannucchi, Ayalew Tefferi

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


In the 2016 revised classification of myeloproliferative neoplasms pre-fibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity, distinct from essential thrombocythemia (ET). Owing that the majority of cases falling in the pre-PMF category were previously diagnosed as ET, one may question about the need to re-evaluate the results of epidemiologic, clinical, and molecular studies, and the results of clinical trials in the two entities. Based on a critical review of recently published studies, pre-PMF usually presents with a distinct clinical and hematological presentation and higher frequency of constitutional symptoms. JAK2V617F and CALR mutations in pre-PMF patients are superimposable to ET, whereas non-driver high-risk mutations are enriched in pre-PMF compared with ET. Thrombosis is not significantly different, whereas bleeding is more frequent in pre-PMF. Median survival is significantly shorter in pre-PMF and 10-year cumulative rates progression to overt myelofibrosis is 0–1% vs. 10–12%, and leukemic transformation is 1–2% vs. 2–6%, in ET and pre-fibrotic-PMF, respectively. Most patients fall in the lower prognostic IPSS group in which observation alone can be recommended. Patients at intermediate risk may require a symptom-driven treatment for anemia, splenomegaly or constitutional symptoms while cytoreductive drugs are indicated in the high-risk category.

Original languageEnglish (US)
Article number22
JournalBlood cancer journal
Issue number2
StatePublished - Feb 1 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The new WHO classification for essential thrombocythemia calls for revision of available evidences'. Together they form a unique fingerprint.

Cite this